The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations
Open accessAbstract
Inhibition of WEE1, a key regulator of the G2/M checkpoint of the cell cycle, induces apoptosis by initiating mitosis without repairing DNA damage. However, the effects of WEE1 inhibitors on the tumor immune microenvironment in colorectal cancer (CRC) remain unclear. Here, we investigated the association between WEE1 expression and CRC clinicopathological features using surgically resected CRC specimens and assessed the antitumor effects of a WEE1 inhibitor using CRC cell lines and orthotopic transplantation mouse models. WEE1 expression was not correlated with the clinicopathological features of CRC. The WEE1 inhibitor suppressed cell proliferation in a concentration-dependent manner in all CRC cell lines. It also increased the percentage of cells in the G2/M phase and apoptotic cells, especially in cell lines with p53 mutations, but did not alter these cell percentages in most p53 wild-type cell lines. In the orthotopic mouse model of CRC, tumor volume was significantly reduced in the WEE1 inhibitor-treated group compared to that in the control group. RNA sequencing and immunohistochemistry analyses of mouse tumors revealed that treatment with the WEE1 inhibitor activated tumor immunity and suppressed stromal reactions. These results demonstrate the potential antitumor effects of WEE1 inhibitors in CRC, particularly in patients with p53 mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A WEE1 inhibitor was recently reported to exert anticancer effects in CRC cells, particularly in those with TP53 mutations [140].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [140]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics
Kanda, Y. (2013) · Bone Marrow Transplantation · doi:10.1038/bmt.2012.244 · Cited by 18,767 · cited 1×
“All statistical analyses were conducted using the EZR software (version 1.60, Saitama Medical Centre, Jichi Medical University, Saitama, Japan) [28].”
MethodInfluentialTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Visualizing and interpreting cancer genomics data via the Xena platform
Goldman, M. J., Craft, B., Hastie, M., Repečka, K., McDade, F., Kamath, A., Banerjee, A., Luo, Y., Rogers, D., Brooks, A. N., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0546-8 · Cited by 4,481 · cited 1×
“Using the University of California, Santa Cruz (UCSC) Cancer Genomics Browser UCSC Xena (https://xena.ucsc.edu/) is an analytical tool used to explore functional genomic datasets and to correlate genomic and phenotypic variables [27].”
MethodTyrosine phosphorylation of the fission yeast cdc2+ protein kinase regulates entry into mitosis
Gould, K. L., & Nurse, P. (1989) · Nature · doi:10.1038/342039a0 · Cited by 1,218 · cited 1×
“WEE1 functions by phosphorylating 15 tyrosine residues of cyclin-dependent kinase 1 (CDK1), thereby inhibiting the activation of the cyclin B–CDK1 complex and the transition from the G2 phase to the M phase of the cell cycle [1,2].”
BackgroundSuppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α
Kraman, M., Bambrough, P. J., Arnold, J. N., Roberts, E. W., Magiera, L., Jones, J. O., Gopinathan, A., Tuveson, D. A., & Fearon, D. T. (2010) · Science · doi:10.1126/science.1195300 · Cited by 1,134 · cited 1×
“Stromal components have been reported to act as barriers to immune cell infiltration in various carcinomas [36–38].”
BackgroundEpigenetic and genetic features of 24 colon cancer cell lines
Ahmed, D., Eide, P. W., Eilertsen, I. A., Danielsen, S. A., Eknæs, M., Hektoen, M., Lind, G. E., & Lothe, R. A. (2013) · Oncogenesis · doi:10.1038/oncsis.2013.35 · Cited by 910
Yemelyanova, A., Vang, R., Kshirsagar, M., Lu, D., Marks, M. A., Shih, I. M., & Kurman, R. J. (2011) · Modern Pathology · doi:10.1038/modpathol.2011.85 · Cited by 513 · cited 1×
“Furthermore, we classified diffuse strong, nested, and negative as p53 mutations and mosaic, sporadic, and diffuse weak as p53 wild types, according to previous reports [25,26].”
ResultTargeting WEE1 Kinase in Cancer
Matheson, C. J., Backos, D. S., & Reigan, P. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.06.006 · Cited by 408 · cited 1×
“WEE1 regulates the initiation of mitosis and arrests the cell cycle in the G2 phase, allowing for DNA repair [3].”
BackgroundCell cycle checkpoints and their inactivation in human cancer
Molinari, M. (2000) · Cell Proliferation · doi:10.1046/j.1365-2184.2000.00191.x · Cited by 388 · cited 1×
“…of genomic instability and apoptosis. p53 and KRAS play crucial roles in cell cycle regulation. p53 is a central regulator of the G1/S checkpoint [4], whereas KRAS mutations induce genomic instability by promoting the transition to the S phase and inducing cell division through sustained CDK2…”
BackgroundMulti-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
Berg, K. C. G., Eide, P. W., Eilertsen, I. A., Johannessen, B., Bruun, J., Danielsen, S. A., Bjørnslett, M., Meza-Zepeda, L. A., Eknæs, M., Lind, G. E., et al. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0691-y · Cited by 382 · cited 2×
“Additionally, in both mouse colon cancer cell lines (CT26 and MC38), the expression level of WEE1 tended to be higher than that in normal The gene mutation statuses (p53 , KRAS , and BRAF ) and MSI of each cell line are shown in Table 4 [29,30]. colonic mucosa.”
Background
Research works printed but not linked: 1
- Yokota, 2016, Evaluation of p53 Protein Overexpression by Immunohistochemistry―Study based on Gene Mutation Analysis, Niigata Igakukai Zassi, 130, 109
Cited by
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“A WEE1 inhibitor was recently reported to exert anticancer effects in CRC cells, particularly in those with TP53 mutations [140].”
Mesenchymal stem cell therapy for premature ovarian insufficiency: progress and challenges
Shao, Z., Liang, L., Xue, Y., Zhu, T., & Wen, Q. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-01976-4 · Cited by 6
“Novel Wee1 inhibitors (e.g. adavosertib) arrest tumour cells in an unscheduled S phase but appear less toxic to quiescent ovarian follicles, although formal reproductive-toxicology data are pending [140, 141].”
Pham, A. T., Yuan, F., Nagathihalli, N. S., & Dosch, A. R. (2026) · Neoplasia · doi:10.1016/j.neo.2026.101309 · Cited by 5
Liu, Y., Wei, X., Chen, N., & Wang, W. (2025) · Discover Oncology · doi:10.1007/s12672-025-03509-9 · Cited by 4
Özdemir, G., & Kaplan, H. M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47070574 · Cited by 3
“The upregulation of WEE1, a key cell cycle regulator, suggests Tempol induces G2/M cell cycle arrest to allow for DNA repair [39].”
Metadata
- Authors
- Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S.
- Affiliations
- Hiroshima University Hospital (JP)
- Corresponding author
- Yuge, Ryo
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2024-09-12
- Volume
- 16
- Issue
- 18
- Pages
- 3136
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11429655
- OpenAlex
- W4402486551
- Cited by
- 12
- References
- 52
- Citations by year
- 2026: 9 · 2025: 3
- FWCI
- 2.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- WEE1 inhibitor, adavosertib, colorectal cancer, TP53 mutation, G2/M checkpoint, DNA damage-induced apoptosis, tumor immune microenvironment, antitumor immunity, tumor stroma, cell proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. https://app.cochat.ai/papers/10.3390/cancers16183136
- The paper
- Ariyoshi, M., Yuge, R., Kitadai, Y., Shimizu, D., Miyamoto, R., Yamashita, K., Hiyama, Y., Takigawa, H., Urabe, Y., & Oka, S. (2024). WEE1 Inhibitor Adavosertib Exerts Antitumor Effects on Colorectal Cancer, Especially in Cases with p53 Mutations. Cancers. https://doi.org/10.3390/cancers16183136
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.